These results were in line with expectation based on the protective role of statins on coronary artery disease and a higher incidence of type II diabetes in statin-treated patients (Cholesterol Treatment Trialists’ Collaboration et al., 2010; Ference et al., 2015; Swerdlow et al., 2015), which suggested that genetic variants included in the HMGCR score can reliably assess the effect of HMG-CoA reductase inhibition. The gene discussed is HMGCR; the disease is type 2 diabetes mellitus.